S6322
Sigma Adjuvant System®
oil
Synonym(s):
Adjuvant System, Sigma Adjuvant
Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
NACRES:
NA.46
UNSPSC Code:
12352203
Application
Adjuvanticity Assay: EIA titer for test mice is at least 2X greater that that of control mice.
Biochem/physiol Actions
Sigma Adjuvant System is a stable oil-in-water emulsion that may be used as an alternative to the classical Freund′s water-in-oil emulsions. It is derived from bacterial and mycobacterial cell wall components that provide potent stimulus to the immune system.
Physical form
Each vial contains 0.5 mg Monophosphoryl Lipid A (detoxified endotoxin) from Salmonella minnesota and 0.5 mg synthetic Trehalose Dicorynomycolate in 2% oil (squalene)-Tween® 80-water.
Legal Information
Sigma Adjuvant System is a registered trademark of Merck KGaA, Darmstadt, Germany
TWEEN is a registered trademark of Croda International PLC
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
signalword
Danger
hcodes
Hazard Classifications
Asp. Tox. 1
Storage Class
10 - Combustible liquids
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, multi-purpose combination respirator cartridge (US)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Related Content
Development of monoclonal antibodies specific for Ricinus agglutinins
Brandon DL and Hernlem BJ
Food and agricultural immunology, 20(1), 11-22 (2009)
Nadja Thönes et al.
Journal of virology, 82(11), 5472-5485 (2008-04-04)
Capsomeres are considered to be an alternative to viruslike particle (VLP)-based vaccines as they can be produced in prokaryotic expression systems. So far, no detailed side-by-side comparison of VLPs and capsomeres has been performed. In the present study, we immunized
Christina Schellenbacher et al.
Journal of virology, 83(19), 10085-10095 (2009-07-31)
The amino (N) terminus of the human papillomavirus (HPV) minor capsid protein L2 can induce low-titer, cross-neutralizing antibodies. The aim of this study was to improve immunogenicity of L2 peptides by surface display on highly ordered, self-assembled virus-like particles (VLP)